The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision. The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision. | | |
|
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. | | |
|
Researchers tracked recent TAVR data from the STS/ACC TVT Registry, highlighting a "concerning" finding they were unable to explain. Researchers tracked recent TAVR data from the STS/ACC TVT Registry, highlighting a "concerning" finding they were unable to explain. | | |
|
The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns. The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns. | | |
|
Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more. Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more. | | |
|
The two newly approved technologies are used together to help visualize cardiac ablation procedures performed with Boston Scientific’s Farapulse pulsed field ablation system. The two newly approved technologies are used together to help visualize cardiac ablation procedures performed with Boston Scientific’s Farapulse pulsed field ablation system. | | |
|
Vegetarian and vegan diets can lower an adult's risk of developing or dying from CVD, according to a new umbrella review of 21 different studies. Researchers believe these findings should be used to influence patient guidelines going forward. Vegetarian and vegan diets can lower an adult's risk of developing or dying from CVD, according to a new umbrella review of 21 different studies. Researchers believe these findings should be used to influence patient guidelines going forward. | | |
|
Shockwave Medical, now a part of Johnson & Johnson MedTech, continues to gain momentum among U.S. cardiologists. According to one MedAxiom executive, IVL "brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease." Shockwave Medical, now a part of Johnson & Johnson MedTech, continues to gain momentum among U.S. cardiologists. According to one MedAxiom executive, IVL "brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease." | | |
|
While production is relatively unchanged compared to the previous year, compensation is up significantly for cardiovascular surgeons in the United States. While production is relatively unchanged compared to the previous year, compensation is up significantly for cardiovascular surgeons in the United States. | | |
|
The Evolut FX+ TAVR system, which already received FDA approval in March, was designed with improved coronary access in mind. One cardiologist described the device as a "significant step forward" for patients with heart disease. The Evolut FX+ TAVR system, which already received FDA approval in March, was designed with improved coronary access in mind. One cardiologist described the device as a "significant step forward" for patients with heart disease. | | |
|
